Cronos Group (NASDAQ: CRON) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its peers? We will compare Cronos Group to similar businesses based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, earnings, risk and valuation.
Risk & Volatility
Cronos Group has a beta of 1.7, indicating that its stock price is 70% more volatile than the S&P 500. Comparatively, Cronos Group’s peers have a beta of 2.56, indicating that their average stock price is 156% more volatile than the S&P 500.
This is a summary of current ratings and target prices for Cronos Group and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Cronos Group Competitors||136||361||413||14||2.33|
Cronos Group presently has a consensus target price of $9.83, suggesting a potential upside of 81.09%. As a group, “Medicinals & botanicals” companies have a potential upside of 111.32%. Given Cronos Group’s peers higher possible upside, analysts clearly believe Cronos Group has less favorable growth aspects than its peers.
Institutional and Insider Ownership
12.1% of Cronos Group shares are held by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 7.9% of Cronos Group shares are held by company insiders. Comparatively, 25.8% of shares of all “Medicinals & botanicals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Earnings & Valuation
This table compares Cronos Group and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Cronos Group||$25.64 million||$1.17 billion||8.10|
|Cronos Group Competitors||$218.50 million||-$99.79 million||1.73|
Cronos Group’s peers have higher revenue, but lower earnings than Cronos Group. Cronos Group is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Cronos Group and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Cronos Group Competitors||-163.69%||-267.59%||-46.37%|
Cronos Group peers beat Cronos Group on 7 of the 13 factors compared.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company in the United States and internationally. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through ecommerce, retail, and hospitality partner channels. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Its brand portfolio includes PEACE NATURALS, a global wellness platform; adult-use brands comprise COVE and Spinach; and hemp-derived CBD brands consists of Lord Jones and PEACE+. Cronos Group Inc. is based in Toronto, Canada.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.